Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLM-101
- Development stage
- Unknown
- Lead developer
- Therillume
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
01
Overview
TLM-101 is an investigational **gene-editing gene therapy** candidate from **Therillume** for **neurofibromatosis type 1**. Publicly available company pipeline materials identify TLM-101 as an NF1 program in **Phase 1**, but do not disclose a specific molecular target, editing construct, delivery system, or route of administration. Based on the company description, the program appears intended to address the underlying genetic basis of NF1 using Therillume's gene-editing platform rather than conventional pathway inhibition; however, the exact editing strategy and product composition have not been publicly described.
Beyond the preview
Go deeper on TLM-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLM-101.